Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Receivables (2018 - 2025)

Historic Receivables for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $4.8 billion.

  • Takeda Pharmaceutical's Receivables rose 224.66% to $4.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.8 billion, marking a year-over-year increase of 224.66%. This contributed to the annual value of $5.0 billion for FY2025, which is 31.4% up from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Receivables of $4.8 billion as of Q4 2025, which was up 224.66% from $4.7 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Receivables high stood at $8.1 billion for Q1 2021, and its period low was $503.8 million during Q1 2023.
  • Its 5-year average for Receivables is $5.1 billion, with a median of $4.9 billion in 2022.
  • Per our database at Business Quant, Takeda Pharmaceutical's Receivables plummeted by 9260.31% in 2022 and then soared by 87016.89% in 2024.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Receivables stood at $6.3 billion in 2021, then decreased by 20.46% to $5.0 billion in 2022, then decreased by 3.22% to $4.8 billion in 2023, then dropped by 3.42% to $4.7 billion in 2024, then grew by 2.25% to $4.8 billion in 2025.
  • Its Receivables was $4.8 billion in Q4 2025, compared to $4.7 billion in Q3 2025 and $4.6 billion in Q2 2025.